Bernstein SocGen lowers BioMarin stock price target on guidance update

BioMarin reported Q1 2026 revenue of $766 million, beating estimates by 1%, and EPS of $0.76 versus $0.74 expected, though the EPS miss was tied to a one-time cost of goods sold item. Bernstein SocGen cut its price target to $82 from $94 while keeping an Outperform rating, and management updated guidance to include Amicus contributions, implying 20% year-over-year company revenue growth versus 5% on a standalone basis. The stock still screens as expensive at a 30.64 P/E, but analyst targets remain broad at $55 to $120.

Analysis

BMRN’s setup is less about the quarter and more about the reset in the market’s expectations for durability of growth. A 20% company-level growth view, even if flattered by acquired contribution, gives the stock a cleaner path to defend a premium multiple because the market usually pays up when top-line acceleration is visible and management can point to a longer runway than a single franchise story. The key second-order effect is that the Amicus tie-in turns the investment debate from “can Voxzogo alone carry valuation?” into “is BioMarin becoming a more resilient rare-disease platform,” which typically supports a higher floor on the stock even if the ceiling is constrained near-term.

The cut in target price is not the important signal; the dispersion of targets is. That wide range tells you positioning is still anchored to very different terminal-growth assumptions, and that creates opportunity if the next few prints confirm that the acquired assets integrate without margin slippage. The main risk is that investors focus on the EPS miss and ignore the quality of the revenue beat; if gross margin dilution from integration or mix shows up over the next 1-2 quarters, the stock can de-rate quickly because the current multiple leaves little room for execution noise.

Contrarian angle: the market may be underestimating how much an incremental, non-Voxzogo revenue stream changes BioMarin’s volatility profile. Lower earnings volatility in a specialty pharma name can justify a higher multiple over a 6-12 month horizon, but only if management avoids the classic M&A trap of promising growth while silently sacrificing operating leverage. That means the trade is more about the next two quarters of margin commentary than the current quarter’s EPS print.

Key Decisions for Investors

• Long BMRN on weakness over the next 1-2 sessions, targeting a 10-15% upside over 3-6 months if guidance credibility holds and margins stay stable; trim if the stock re-rates above the high end of sell-side targets without follow-through in next-quarter commentary.
• Buy BMRN call spreads 3-6 months out to express upside from multiple support while capping premium burn; best risk/reward if implied volatility stays elevated after earnings and the stock consolidates rather than gaps higher.
• Pair trade: long BMRN / short a higher-multiple commercial-stage biotech with less diversified revenue and no fresh guidance reset, to isolate the valuation benefit from improved growth visibility over a 1-3 month horizon.
• Use a tactical stop if management signals integration-related gross margin pressure or if next-quarter guidance is revised down; that would undermine the main thesis and could trigger a fast 8-12% de-rating.
• For more defensive exposure, hold BMRN only as a partial position until the market gets one more clean quarter of execution, since the current multiple leaves limited room for any operational disappointment.